We welcome their investment as we pursue our near-term strategic objectives and continue our discussions with the FDA regarding a randomized controlled study in acute complete thoracic spinal cord
injury that evaluates the Neuro-Spinal Scaffold compared to standard of care.
The objective performance criterion (study success definition) for the study was a 25% AIS conversion rate based on the published conversion rates for thoracic spinal cord
injury reported in the literature.
I was diagnosed with an intradural thoracic spinal cord
tumour that had severely compressed my spinal cord and caused paralysis.
n a previous Phase 1 clinical trial, five patients with neurologically complete, thoracic spinal cord
injury were administered two million AST OPC1 cells at the spinal cord injury site 7-14 days post-injury.
T1- and T2-weighted MRI images revealed a solid-cystic lesion of the cervical and thoracic spinal cord
, which spread from the level of the C1–T3 vertebrae with areas of isointense signals and moderate enhancements [Figure 1]a,[Figure 1]b,[Figure 1]c,[Figure 1]d.
An emergent decompression of the thoracic spine was performed with an intraoperative ultrasound confirming liquefied material within the upper thoracic spinal cord
, compatible with intramedullary abscess formation.
He was shot in the jaw which caused damage to his lower cervical and upper thoracic spinal cord
and severed multiple vital arteries.
Thoracic spinal cord
compression indicating Wegener's granulomatosis in a patient with a previous presumptive diagnosis of microscopic polyangiitis.
Using a mouse model of thoracic spinal cord
contusion injury, the researchers divided the mice into rapamycin-treated and control groups.
Under the company's prior Phase 1 clinical trial, five patients with neurologically complete, thoracic spinal cord
injury were administered 2m AST-OPC1 cells at the spinal cord injury site post-injury.
Dural arteriovenous fistulas (DAVF) are the most common spinal cord vascular malformation and most often affect the thoracic spinal cord
The foundation for the clinical trial comes from results from the phase I clinical trial of AST-OPC1, which met its primary endpoints of safety and feasibility when administered to five patients with neurologically complete, thoracic spinal cord